Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06679829RecruitingPhase 2
Melphalan with or without siltuximab for multiple myeloma stem cell transplant
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
Basking Ridge, New JerseyAges 60 years+ - NCT06680037RecruitingPhase 1
Azer-cel for autoimmune disorders like MS, NMOSD, MG, and CIDP
This trial tests an investigational cell therapy called Azer-cel in people with certain autoimmune diseases that affect the nerves or muscles. It aims to see if the treatment is safe and can help reduce symptoms by targeting the immune system.
La Jolla, CaliforniaAges 18 years+ - NCT06680388RecruitingEarly Phase 1
CD19 CAR-T for severe autoimmune diseases
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06680661RecruitingPhase 2
Double cord blood transplant with abatacept for GVHD prevention
This trial tests whether adding abatacept to a double cord blood transplant can prevent graft-versus-host disease (GVHD) in people with certain blood cancers. You may qualify if you have high-risk leukemia or other blood disorders and do not have a matched related or unrelated donor.
Cleveland, OhioAges 18–65 - NCT06681363Recruiting
Leukemia and MDS biobank study at Nantes Hospital
This trial creates a biobank of blood or bone marrow samples from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or high-risk myelodysplastic syndrome (MDS). It aims to collect samples for future research, which may help develop better treatments.
NantesAges 18 years+ - NCT06681545Recruiting
Living with severe asthma as a young adult
This study explores what it's like to live with severe asthma as a young adult. It uses interviews or focus groups to understand your experiences, to help improve care for others like you.
Manchester, GreaterAges 16–25 - NCT06681623Recruiting
Ublituximab in older adults with relapsing MS
This study is testing how safe and effective the medication ublituximab is for older adults (ages 55–80) with relapsing multiple sclerosis. It aims to see if this treatment works well for this age group.
Foxborough, MassachusettsAges 55–80 - NCT06681922RecruitingPhase 1/Phase 2
A new combination to prevent graft-versus-host disease after stem cell transplant
This study tests a combination of three drugs—high-dose cyclophosphamide, bortezomib, and abatacept—after a donor stem cell transplant to see if they can better prevent graft-versus-host disease (a condition where donor cells attack the body).
Lake Success, New YorkAges 18 years+ - NCT06682130RecruitingPhase 2
Glofitamab before stem cell transplant for relapsed DLBCL
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Suzhou, JiangsuAges 18–70 - NCT06682169RecruitingPhase 3
New pill for chronic graft-versus-host disease after other treatments fail
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
Hefei, AnhuiAges 18–70 - NCT06682507Recruiting
Lupus nephritis long-term study
This study follows patients with lupus nephritis (kidney inflammation caused by lupus) over time to learn more about the disease and improve care. You may join if you have had a kidney biopsy confirming lupus nephritis at this hospital.
Guangzhou, GuangdongAges 14 years+ - NCT06683391Recruiting
Improving Low Blood Sugar Guidelines for Type 1 Diabetes
This study is looking for adults with type 1 diabetes to help improve guidelines for preventing and treating low blood sugar (hypoglycemia). The goal is to make recommendations that are more practical and safer for people like you.
Montreal, QuebecAges 18 years+ - NCT06683521Recruiting
Understanding the immune system in FPIES
This study looks at how the immune system works in people with Food Protein-Induced Enterocolitis Syndrome (FPIES). It aims to learn more about this condition to improve future diagnosis and treatment.
New York, New YorkAges 1–60 - NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT06685055Recruiting
Finding markers of good response to fcRn inhibitors in myasthenia gravis
This study looks for markers that might predict who will respond well to a new class of medicines called FcRn inhibitors. These medicines help reduce harmful antibodies that attack nerves and muscles in people with a certain type of Myasthenia Gravis. The goal is to better personalize treatment for patients in Italy.
RomeAges 18 years+ - NCT06685744Recruiting
Tele-rehab for Parkinson's or MS
This trial tests if a home-based tele-rehabilitation program helps people with Parkinson's disease or multiple sclerosis. It aims to improve movement and daily life through guided remote sessions.
BariAges 25–85 - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55 - NCT06686329Recruiting
Exercise for blood sugar correction after insulin timing error
This trial looks at whether physical activity can help treat or prevent high blood sugar caused by taking a rapid-acting insulin dose at the wrong time. If you are a young adult with type 1 diabetes and use a Dexcom G7 continuous glucose monitor, this study may help you learn how to use exercise as a tool for managing unexpected blood sugar spikes.
Montreal, QuebecAges 18–24 - NCT06686472RecruitingPhase 2
Testing TL-925 eye drops for allergic conjunctivitis
This trial tests an investigational eye drop called TL-925 to see if it can treat allergic conjunctivitis (eye allergies). If you have a history of eye allergies and a positive allergy skin test, you may be able to join.
Memphis, TennesseeAges 18 years+ - NCT06686927RecruitingPhase 2
Steroids, IVIG, and romiplostim for severe ITP
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Wuhan, HubeiAges 18–75 - NCT06687434Recruiting
Carb counting vs. simple meal-size estimation for type 1 diabetes
This study compares two ways of estimating meal size for people with type 1 diabetes who use automated insulin delivery systems. One method is detailed carb counting, the other is a simpler, qualitative estimate of meal size. The goal is to see which approach works better for managing blood sugar.
Petah TikvaAges 6–18 - NCT06688799RecruitingPhase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Beijing, Beijing MunicipalityAges 3–65 - NCT06689800Recruiting
Family communication tool for kids getting transplant or cell therapy
This study looks at a family communication tool for children and teens getting stem cell transplants or cellular therapy. It helps families talk about treatment together.
St Louis, MissouriAges 8 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.